IL2RA expression

This activation was specifically abolished by ICOSL blockade, establishing the functional significance of this pathway. Our findings provide novel insights into tumor-immune interactions in cholangiocarcinoma and suggest the ICOS-ICOSL axis as a potential therapeutic target for immunotherapy.

We confirmed that SABR stimulates the immune system, which impacts patient clinical outcomes. A simultaneous increase in the percentage of PD-1+ lymphocytes and upregulation of Th17 response after SABR is an independent favorable prognostic factor.

The kit can be stored at -80 °C up to 6 months, thus facilitating the adoption of 68Ga-THP-desIL2 into clinical practice. 68Ga-THP-desIL2 showed high affinity and specificity for CD25 on activated T-lymphocytes, particularly Tregs, thus opening new opportunities for imaging immune cells trafficking in the TME.

Class I KIT activating mutations are linked to mostly intracellular expression of aberrant MC immunophenotypes and the WDSM morphological pattern.

Our findings support the temporally optimized use of CD25-biased IL-2-based therapeutics in combination with ICIs for cancer immunotherapy.

Furthermore, this method improves T cell adherence, proliferation, and functional effectiveness, offering a potential foundation for advancing CAR-T cell therapies aimed at solid tumors. Future research should concentrate on optimizing culture conditions and testing this method in preclinical animal models to ensure its clinical applicability and efficacy.

P1, N=7, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=12 --> 7

most cases of ALK+ ALCL highly express CD25 which is a potential target for therapy. ALK+ ALCL with low CD25 expression is associated with older patient age and increased frequency of thrombocytopenia and surface CD3 and CD8 expression.

In addition to direct targeting of CD25 expressing tumor cells, both drugs are also capable of depleting immunoregulatory T-cells. A clinical trial of DD-cxdl in Japan showed that responses were independent of CD25 expression, suggesting multiple mechanisms of action for DD-cxdl in MF/SS and potentially other malignancies.

Furthermore, C-MYC was significantly upregulated in CACRC epithelial cells, suggesting its role in tumor proliferation and metabolic reprogramming. This study uncovers dynamic cellular and molecular changes during the transition from UC to CACRC, highlighting IL-17 signaling, Treg expansion, and C-MYC activation as potential drivers of malignancy and targets for future therapeutic intervention.

IL27RA is a potential immune biomarker that reflects an inflamed tumor microenvironment and predicts benefit from immunotherapy and chemotherapy in breast cancer. These findings provide novel insights into immune-based stratification using single-cell transcriptomic data.

Our findings demonstrate that CARs can detect and discriminate between tau PFFs, Aβ1-42, and Aβp3-42 aggregates. This highlights the potential of repurposing AD antibodies for CAR-based therapies to selectively target tau NFTs and distinct forms of Aβ senile plaques.